Loading patent…
AssigneeCentre for Chinese Herbal Medicine Drug Development Limited
InventorsZhaoxiang BIAN, Lixiang ZHAI, Xavier Hoi Leong WONG, Ziwan NING, Shujun XU, Junfang LYU, Gengyu BAO
Estimating the term…
The present invention discloses use of hyocholic acid (HCA)-based bile acid species in the preparation of a medicament for the treatment of irritable bowel syndrome (IBS). It was discovered in the present invention that the content of HCA species in the feces of IBS-D patients treated with traditional Chinese medicine was significantly increased. Moreover, HCA species were significantly reduced in fecal samples of IBS-D patients compared with healthy controls. Further research revealed that HDCA and natural traditional Chinese medicine PULVIS FELLIS SUIS can reduce the peripheral serotonin level by inhibiting the activity of tryptophan hydroxylase 1, and significantly improve the symptoms of diarrhea and abdominal pain in TNBS-induced mice, indicating an application value of HCA species in treating IBS-D.
A method for preventing or treating Irritable Bowel Syndrome with Diarrhea (IBS-D), comprising administering a therapeutically effective amount of a hyocholic acid based bile acid species (HCA species) and/or a crude drug comprising an HCA species to a subject in need thereof.
A pharmaceutical composition for treating IBS-D, comprising an HCA species and/or a crude drug comprising an HCA species.
A method for inhibiting TPH1 activity in a subject with IBS-D, comprising administering an HCA species or a crude drug comprising an HCA species to the subject.
Dependencies are inferred from the claim text.